{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:46Z","timestamp":1790812126388,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-024-02389-2","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T02:59:58Z","timestamp":1742612398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety and efficacy of antisense oligonucleotides on triglyceride, apolipoprotein C-III, and other lipid parameters levels in hypertriglyceridemia; a network meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"24","author":[{"given":"Abdelrahman","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerollos","family":"Abdelsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Almahdy","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qasi","family":"Najah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Abdulkader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehroze","family":"Tabassum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Riad","family":"Abouzid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel","family":"Abdelazeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"2389_CR1","doi-asserted-by":"publisher","unstructured":"Kumari A, Kristensen KK, Ploug M, Winther AML. The importance of lipoprotein lipase regulation in atherosclerosis. Biomed [Internet]. 2021;9(7):782. https:\/\/doi.org\/10.3390\/biomedicines9070782","DOI":"10.3390\/biomedicines9070782"},{"key":"2389_CR2","doi-asserted-by":"publisher","unstructured":"Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep [Internet]. 2011;13(6):544\u201352. https:\/\/doi.org\/10.1007\/s11886-011-0220-3","DOI":"10.1007\/s11886-011-0220-3"},{"key":"2389_CR3","doi-asserted-by":"publisher","unstructured":"Xu J, Ashjian E. Treatment of Hypertriglyceridemia: A review of therapies in the pipeline. J Pharm Pract [Internet]. 2021;36(3):650\u201361. https:\/\/doi.org\/10.1177\/08971900211053489","DOI":"10.1177\/08971900211053489"},{"key":"2389_CR4","doi-asserted-by":"publisher","unstructured":"Nordestgaard BG. Triglyceride-Rich lipoproteins and atherosclerotic cardiovascular disease. Circ Res [Internet]. 2016;118(4):547\u201363. https:\/\/doi.org\/10.1161\/circresaha.115.306249","DOI":"10.1161\/circresaha.115.306249"},{"key":"2389_CR5","doi-asserted-by":"publisher","unstructured":"Fujioka Y, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis.  J Atheroscler Thromb [Internet]. 2009;16(3):145\u201354. https:\/\/doi.org\/10.5551\/jat.e598","DOI":"10.5551\/jat.e598"},{"key":"2389_CR6","doi-asserted-by":"publisher","unstructured":"Tenenbaum A, Klempfner R, Fisman EZ. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol [Internet]. 2014;13(1). https:\/\/doi.org\/10.1186\/s12933-014-0159-y","DOI":"10.1186\/s12933-014-0159-y"},{"key":"2389_CR7","doi-asserted-by":"publisher","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APHA\/, ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol. Executive Summary. J Am Coll Cardiol [Internet]. 2018;73(24):3168\u2013209. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.002","DOI":"10.1016\/j.jacc.2018.11.002"},{"key":"2389_CR8","doi-asserted-by":"publisher","unstructured":"Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England J Med [Internet]. 2011;365(24):2255\u201367. https:\/\/doi.org\/10.1056\/nejmoa1107579","DOI":"10.1056\/nejmoa1107579"},{"key":"2389_CR9","doi-asserted-by":"publisher","unstructured":"Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P et al. Effects of combination lipid therapy in Type 2 diabetes mellitus. New England J Med [Internet]. 2010;362(17):1563\u201374. https:\/\/doi.org\/10.1056\/nejmoa1001282","DOI":"10.1056\/nejmoa1001282"},{"key":"2389_CR10","doi-asserted-by":"publisher","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England J Med [Internet]. 2004;350(15):1495\u2013504. https:\/\/doi.org\/10.1056\/nejmoa040583","DOI":"10.1056\/nejmoa040583"},{"key":"2389_CR11","doi-asserted-by":"publisher","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. New England J Med [Internet]. 2005;352(14):1425\u201335. https:\/\/doi.org\/10.1056\/nejmoa050461","DOI":"10.1056\/nejmoa050461"},{"key":"2389_CR12","doi-asserted-by":"publisher","unstructured":"Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England J Med [Internet]. 2014;371(3):203\u201312. https:\/\/doi.org\/10.1056\/nejmoa1300955","DOI":"10.1056\/nejmoa1300955"},{"key":"2389_CR13","doi-asserted-by":"publisher","unstructured":"Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New England J Med [Internet]. 1999;341(6):410\u20138. https:\/\/doi.org\/10.1056\/nejm199908053410604","DOI":"10.1056\/nejm199908053410604"},{"key":"2389_CR14","doi-asserted-by":"publisher","unstructured":"Dash S, Xiao C, Morgantini C, Lewis GF. New insights into the regulation of chylomicron production. Annu Rev Nutr [Internet]. 2015;35(1):265\u201394. https:\/\/doi.org\/10.1146\/annurev-nutr-071714-034338","DOI":"10.1146\/annurev-nutr-071714-034338"},{"key":"2389_CR15","doi-asserted-by":"publisher","unstructured":"Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG et al. Targeting APOC3 in the familial chylomicronemia syndrome. New England J Med [Internet]. 2014;371(23):2200\u20136. https:\/\/doi.org\/10.1056\/nejmoa1400284","DOI":"10.1056\/nejmoa1400284"},{"key":"2389_CR16","doi-asserted-by":"publisher","unstructured":"Norata GD, Tsimikas S, Pirillo A, Catapano AL, Apolipoprotein C-III. From pathophysiology to pharmacology. Trends Pharmacol Sci [Internet]. 2015;36(10):675\u201387. https:\/\/doi.org\/10.1016\/j.tips.2015.07.001","DOI":"10.1016\/j.tips.2015.07.001"},{"key":"2389_CR17","doi-asserted-by":"publisher","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Loss-of-function mutations inAPOC3and risk of ischemic vascular disease. New England J Med [Internet]. 2014;371(1):32\u201341. https:\/\/doi.org\/10.1056\/nejmoa1308027","DOI":"10.1056\/nejmoa1308027"},{"key":"2389_CR18","doi-asserted-by":"publisher","unstructured":"Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W et al. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. New England J Med [Internet]. 2015;373(5):438\u201347. https:\/\/doi.org\/10.1056\/nejmoa1400283","DOI":"10.1056\/nejmoa1400283"},{"key":"2389_CR19","doi-asserted-by":"publisher","unstructured":"Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia. JAMA Cardiol [Internet]. 2024;9(7):620. https:\/\/doi.org\/10.1001\/jamacardio.2024.0959","DOI":"10.1001\/jamacardio.2024.0959"},{"key":"2389_CR20","doi-asserted-by":"publisher","unstructured":"Tardif JC, Karwatowska-Prokopczuk E, St Amour E, Ballantyne CM, Shapiro MD, Moriarty PM et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. European Heart J [Internet]. 2021;43(14):1401\u201312. https:\/\/doi.org\/10.1093\/eurheartj\/ehab820","DOI":"10.1093\/eurheartj\/ehab820"},{"key":"2389_CR21","doi-asserted-by":"publisher","unstructured":"Esan O, Wierzbicki AS. Volanesorsen in the treatment of familial chylomicronemia syndrome or hypertriglyceridaemia: design, development and place in therapy [Internet]. 2020 Jul 1;Volume 14:2623\u201336. Available from: https:\/\/doi.org\/10.2147\/dddt.s224771","DOI":"10.2147\/dddt.s224771"},{"key":"2389_CR22","doi-asserted-by":"publisher","unstructured":"Dai W, Zhang Z, Yao C, Zhao S. Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease. Lipids Health Dis [Internet]. 2019;18(1). https:\/\/doi.org\/10.1186\/s12944-019-1166-5","DOI":"10.1186\/s12944-019-1166-5"},{"key":"2389_CR23","doi-asserted-by":"publisher","unstructured":"Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG et al. Antisense-Mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in Type 2 diabetes. Diabetes Care [Internet]. 2016;39(8):1408\u201315. https:\/\/doi.org\/10.2337\/dc16-0126","DOI":"10.2337\/dc16-0126"},{"key":"2389_CR24","doi-asserted-by":"publisher","unstructured":"Yang X, Lee SR, Choi YS, Alexander VJ, Digenio A, Yang Q et al. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res [Internet]. 2016;57(4):706\u201313. https:\/\/doi.org\/10.1194\/jlr.m066399","DOI":"10.1194\/jlr.m066399"},{"key":"2389_CR25","doi-asserted-by":"publisher","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. New England J Med [Internet]. 2019;381(6):531\u201342. https:\/\/doi.org\/10.1056\/nejmoa1715944","DOI":"10.1056\/nejmoa1715944"},{"key":"2389_CR26","doi-asserted-by":"publisher","unstructured":"Oral EA, Garg A, Tami J, Huang EA, O\u2019Dea LStL, Schmidt H et al. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study. J Clin Lipidol [Internet]. 2022;16(6):833\u201349. https:\/\/doi.org\/10.1016\/j.jacl.2022.08.008","DOI":"10.1016\/j.jacl.2022.08.008"},{"key":"2389_CR27","doi-asserted-by":"publisher","unstructured":"Lightbourne M, Startzell M, Bruce KD, Brite B, Muniyappa R, Skarulis M et al. Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy. J Clin Lipidol [Internet]. 2022;16(6):850\u201362. https:\/\/doi.org\/10.1016\/j.jacl.2022.06.011","DOI":"10.1016\/j.jacl.2022.06.011"},{"key":"2389_CR28","doi-asserted-by":"publisher","unstructured":"Schmitz J, Gouni-Berthold I. APOC-III Antisense oligonucleotides: a new option for the treatment of hypertriglyceridemia. Curr Med Chem [Internet]. 2018;25(13):1567\u201376. https:\/\/doi.org\/10.2174\/0929867324666170609081612","DOI":"10.2174\/0929867324666170609081612"},{"key":"2389_CR29","doi-asserted-by":"publisher","unstructured":"Rocha NA, East C, Zhang J, McCullough PA. APOCIII as a cardiovascular risk factor and modulation by the novel Lipid-Lowering agent Volanesorsen. Curr Atheroscler Rep [Internet]. 2017;19(12). https:\/\/doi.org\/10.1007\/s11883-017-0697-3","DOI":"10.1007\/s11883-017-0697-3"},{"key":"2389_CR30","doi-asserted-by":"publisher","unstructured":"Chebli J, Larouche M, Gaudet D. APOC3 siRNA and ASO therapy for dyslipidemia. Curr Opin Endocrinol Diabetes Obes [Internet]. 2024;31(2):70\u20137. https:\/\/doi.org\/10.1097\/med.0000000000000857","DOI":"10.1097\/med.0000000000000857"},{"key":"2389_CR31","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021;n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"2389_CR32","doi-asserted-by":"publisher","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for systematic reviews of interventions. Cochrane Library [Internet]. 2019; https:\/\/doi.org\/10.1002\/14651858.ed000142","DOI":"10.1002\/14651858.ed000142"},{"key":"2389_CR33","unstructured":"Covidence. Covidence - Better systematic review management [Internet]. Covidence. 2024. https:\/\/www.covidence.org\/"},{"key":"2389_CR34","doi-asserted-by":"publisher","unstructured":"Sterne Ja, C, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019;l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"2389_CR35","doi-asserted-by":"publisher","unstructured":"Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Sch\u00fcnemann HJ. What is quality of evidence and why is it important to clinicians? BMJ [Internet]. 2008;336(7651):995\u20138. https:\/\/doi.org\/10.1136\/bmj.39490.551019.be","DOI":"10.1136\/bmj.39490.551019.be"},{"key":"2389_CR36","doi-asserted-by":"publisher","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ [Internet]. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.ad","DOI":"10.1136\/bmj.39489.470347.ad"},{"key":"2389_CR37","doi-asserted-by":"publisher","unstructured":"Gaudet D, Clifton P, Sullivan D, Baker J, Schwabe C, Thackwray S et al. RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia. NEJM Evidence [Internet]. 2023;2(12). https:\/\/doi.org\/10.1056\/evidoa2200325","DOI":"10.1056\/evidoa2200325"},{"key":"2389_CR38","doi-asserted-by":"publisher","unstructured":"Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes & Endocrinol [Internet]. 2021;9(5):264\u201375. https:\/\/doi.org\/10.1016\/s2213-8587(21)00046-2","DOI":"10.1016\/s2213-8587(21)00046-2"},{"key":"2389_CR39","doi-asserted-by":"publisher","unstructured":"Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. New England J Med [Internet]. 2024;390(19):1781\u201392. https:\/\/doi.org\/10.1056\/nejmoa2400201","DOI":"10.1056\/nejmoa2400201"},{"key":"2389_CR40","doi-asserted-by":"publisher","unstructured":"Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. New England J Med [Internet]. 2024;391(10):899\u2013912. https:\/\/doi.org\/10.1056\/nejmoa2404143","DOI":"10.1056\/nejmoa2404143"},{"key":"2389_CR41","doi-asserted-by":"publisher","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. New England J Med [Internet]. 2024;390(19):1770\u201380. https:\/\/doi.org\/10.1056\/nejmoa2402309","DOI":"10.1056\/nejmoa2402309"},{"key":"2389_CR42","doi-asserted-by":"publisher","unstructured":"Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH et al. Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline. J Clin Endocrinol & Metabolism [Internet]. 2012;97(9):2969\u201389. https:\/\/doi.org\/10.1210\/jc.2011-3213","DOI":"10.1210\/jc.2011-3213"},{"key":"2389_CR43","doi-asserted-by":"publisher","unstructured":"Murphy MJ, Sheng X, MacDonald TM, Wei L. Hypertriglyceridemia and acute pancreatitis. JAMA Int Med [Internet]. 2012;173(2):162. https:\/\/doi.org\/10.1001\/2013.jamainternmed.477","DOI":"10.1001\/2013.jamainternmed.477"},{"key":"2389_CR44","doi-asserted-by":"publisher","unstructured":"Christian JB, Arondekar B, Buysman EK, Jacobson TA, Snipes RG, Horwitz RI. Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia. Am J Med [Internet]. 2013;127(1):36\u201344.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2013.09.018","DOI":"10.1016\/j.amjmed.2013.09.018"},{"key":"2389_CR45","doi-asserted-by":"publisher","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England J Med [Internet]. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/nejmoa1615664","DOI":"10.1056\/nejmoa1615664"},{"key":"2389_CR46","doi-asserted-by":"publisher","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England J Med [Internet]. 2018;380(1):11\u201322. https:\/\/doi.org\/10.1056\/nejmoa1812792","DOI":"10.1056\/nejmoa1812792"},{"key":"2389_CR47","doi-asserted-by":"publisher","unstructured":"Tonkin A, Alyward P, Colquhoun D, Glasziou P, Harris P, Hunt D et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England J Med [Internet]. 1998;339(19):1349\u201357. https:\/\/doi.org\/10.1056\/nejm199811053391902","DOI":"10.1056\/nejm199811053391902"},{"key":"2389_CR48","doi-asserted-by":"publisher","unstructured":"Shoulders CC. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet [Internet]. 2004;13(90001):149R \u2013 160. https:\/\/doi.org\/10.1093\/hmg\/ddh069","DOI":"10.1093\/hmg\/ddh069"},{"key":"2389_CR49","doi-asserted-by":"publisher","unstructured":"Balling M, Afzal S, Smith GD, Varbo A, Langsted A, Kamstrup PR et al. Elevated LDL triglycerides and atherosclerotic risk. J Am Coll Cardiol [Internet]. 2023;81(2):136\u201352. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.019","DOI":"10.1016\/j.jacc.2022.10.019"},{"key":"2389_CR50","doi-asserted-by":"publisher","unstructured":"Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering. JAMA [Internet]. 2018;319(15):1566. https:\/\/doi.org\/10.1001\/jama.2018.2525","DOI":"10.1001\/jama.2018.2525"},{"key":"2389_CR51","doi-asserted-by":"publisher","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart J [Internet]. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"2389_CR52","doi-asserted-by":"publisher","unstructured":"Srikanth S, Deedwania P. Management of dyslipidemia in patients with hypertension, diabetes, and metabolic syndrome. Curr Hypertens Rep [Internet]. 2016;18(10). https:\/\/doi.org\/10.1007\/s11906-016-0683-0","DOI":"10.1007\/s11906-016-0683-0"},{"key":"2389_CR53","doi-asserted-by":"publisher","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet [Internet]. 2004;364(9435):685\u201396. https:\/\/doi.org\/10.1016\/s0140-6736(04)16895-5","DOI":"10.1016\/s0140-6736(04)16895-5"},{"key":"2389_CR54","doi-asserted-by":"publisher","unstructured":"Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England J Med [Internet]. 2008;359(21):2195\u2013207. https:\/\/doi.org\/10.1056\/nejmoa0807646","DOI":"10.1056\/nejmoa0807646"},{"key":"2389_CR55","doi-asserted-by":"publisher","unstructured":"Bloomgarden ZT. Dyslipidemia and the metabolic syndrome. Diabetes Care [Internet]. 2004;27(12):3009\u201316. https:\/\/doi.org\/10.2337\/diacare.27.12.3009","DOI":"10.2337\/diacare.27.12.3009"},{"key":"2389_CR56","doi-asserted-by":"publisher","unstructured":"Singh S, Bittner V. Familial hypercholesterolemia\u2014epidemiology, diagnosis, and screening. Curr Atheroscler Rep [Internet]. 2015;17(2). https:\/\/doi.org\/10.1007\/s11883-014-0482-5","DOI":"10.1007\/s11883-014-0482-5"},{"key":"2389_CR57","doi-asserted-by":"publisher","unstructured":"Langlois MR, Sniderman AD. Non-HDL cholesterol or APOB: which to prefer as a target for the prevention of atherosclerotic cardiovascular disease? Curr Cardiol Rep [Internet]. 2020;22(8). https:\/\/doi.org\/10.1007\/s11886-020-01323-z","DOI":"10.1007\/s11886-020-01323-z"},{"key":"2389_CR58","doi-asserted-by":"publisher","unstructured":"Ferhatbegovi\u0107 L, Mr\u0161i\u0107 D, Ku\u0161ljugi\u0107 S, Pojski\u0107 B. LDL-C: the only causal risk factor for ASCVD. Why is it still overlooked and underestimated? Curr Atheroscler Rep  [Internet]. 2022;24(8):635\u201342. https:\/\/doi.org\/10.1007\/s11883-022-01037-3","DOI":"10.1007\/s11883-022-01037-3"},{"key":"2389_CR59","doi-asserted-by":"publisher","unstructured":"Kontush A. HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovasc Res [Internet]. 2014;103(3):341\u20139. https:\/\/doi.org\/10.1093\/cvr\/cvu147","DOI":"10.1093\/cvr\/cvu147"},{"key":"2389_CR60","doi-asserted-by":"publisher","unstructured":"Xiao C, Dash S, Morgantini C, Hegele RA, Lewis GF. Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol. Diabetes [Internet]. 2016;65(7):1767\u201378. https:\/\/doi.org\/10.2337\/db16-0046","DOI":"10.2337\/db16-0046"},{"key":"2389_CR61","doi-asserted-by":"publisher","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. New England J Med [Internet]. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/nejmoa1801174","DOI":"10.1056\/nejmoa1801174"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02389-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-024-02389-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02389-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T08:04:11Z","timestamp":1746691451000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-024-02389-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2389"],"URL":"https:\/\/doi.org\/10.1186\/s12944-024-02389-2","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors reported that the references 26 and 27 in the references section were reversed.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}